CSL Ltd
ASX:CSL
CSL Ltd
Operating Income
CSL Ltd
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
CSL Ltd
ASX:CSL
|
Operating Income
$3.9B
|
CAGR 3-Years
10%
|
CAGR 5-Years
9%
|
CAGR 10-Years
9%
|
|
|
Immutep Ltd
ASX:IMM
|
Operating Income
-AU$50.4m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-14%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Operating Income
-$66.9m
|
CAGR 3-Years
10%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Operating Income
AU$55.3m
|
CAGR 3-Years
18%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Operating Income
AU$79.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Operating Income
-AU$37.6m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
-22%
|
|
CSL Ltd
Glance View
In the bustling world of biotech innovation, CSL Limited stands as a stalwart, renowned for not just navigating but shaping the industry's intricate landscape. Founded in 1916, this Australian giant has grown from its humble beginnings to become a global leader in the biopharmaceutical sector. CSL operates primarily through two main segments: CSL Behring and Seqirus. CSL Behring is the cornerstone of the company's growth, specializing in the development of life-saving therapies derived from human plasma. These therapies are pivotal in treating rare and serious diseases such as hemophilia, immune deficiencies, and hereditary angioedema. The company has built an impressive collection of facilities across several continents, focusing on plasma collection and processing, which underscores its commitment to advanced therapeutic solutions. Alongside CSL Behring, Seqirus has emerged as a formidable force in the influenza vaccine market and is now one of the world's largest flu vaccine providers. The acquisition and transformation of this division signify CSL’s strategic expansion into broader preventive healthcare. From developing and distributing advanced technologies in cell-based and adjuvanted influenza vaccines to advancing research in universal flu vaccines, Seqirus exemplifies CSL's innovative spirit. Collectively, these divisions illustrate how CSL marries cutting-edge research with robust global operations to generate robust revenues, addressing pressing healthcare needs across the globe while promising new horizons in medical science.
See Also
What is CSL Ltd's Operating Income?
Operating Income
3.9B
USD
Based on the financial report for Dec 31, 2024, CSL Ltd's Operating Income amounts to 3.9B USD.
What is CSL Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
9%
Over the last year, the Operating Income growth was 7%. The average annual Operating Income growth rates for CSL Ltd have been 10% over the past three years , 9% over the past five years , and 9% over the past ten years .
You don't have any saved screeners yet